Developer docs
API playgroundTry for free, no card

Search company profiles

CroíValve

Full company profile

uuid0000cgo

Namestring
CroíValve
Legal namestring
CroíValve
Websiteurl
croivalve.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

CroíValve is a clinical-stage medical device company developing the DUO™ System, a transcatheter tricuspid coaptation valve for the minimally invasive treatment of severe or greater symptomatic Tricuspid Regurgitation (TR). The device is designed to fill the regurgitant leak by working in tandem with the native tricuspid valve leaflets, preserving native anatomy and remaining independent of annulus size and coaptation gap. It is anchored in the Superior Vena Cava (SVC) via a stent, leaving the right heart and native valve apparatus untouched, and is compatible with pre-existing cardiac implantable electronic device (CEID) leads. The product line now includes the DUO Adapt System, which introduces "Adaptive Coaptation" capable of treating very large leaks up to 35mm.

The company's go-to-market is structured around clinical evidence generation rather than commercial sales. Two ongoing studies support the technology: TANDEM I (first-in-human, completed in Europe with 10 patients showing 89% KCCQ improvement, 100% NYHA Class I/II at 6 months, zero pacemaker events, and 100% survival) and TANDEM II (FDA-approved Early Feasibility Study underway at US and EU sites including Piedmont Heart Institute, with more than 15 patients treated and expanding). The DUO System is not commercially available in any geography, and the company has stated no pricing. Future commercialization is planned through direct sales to hospitals and heart valve centers following regulatory approval.

CroíValve is headquartered in Dublin, Ireland with R&D and Operations in Galway, and Clinical/Regulatory functions in the United States. Founded in 2016 by Dr. Martin Quinn (an interventional cardiologist who performed Ireland's first TAVI in 2008) and Dr. Lucy O'Keeffe (ex-Medtronic transcatheter aortic program), the company has raised approximately $43 million including grants through a Series A (€8M, 2022), Series B ($16M, 2024), an EIC Accelerator award (€2.5M grant + €10M equity commitment, 2025), and a Series B expansion ($20M + $7M grants, 2026). Key investors include MedTech Syndicate, BGF, the European Innovation Council, Broadview Ventures, HBAN MedTech, Irrus Syndicates, Enterprise Ireland, IAG Capital Partners, Ascentifi, Furthr, Atlantic Bridge University Fund, Elkstone, and SOSV.

Short descriptiontext

CroíValve is a clinical-stage medical device company developing the DUO™ System, a transcatheter tricuspid coaptation valve that works with the native valve to treat severe Tricuspid Regurgitation, currently in FDA early feasibility studies targeting an estimated 4M+ patients in the US and EU.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transcatheter heart valve, tricuspid regurgitation device, structural heart intervention, minimally invasive cardiac implant, coaptation valve system
Industry2 codes
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKAHAN
Critical Care Nephrology (ICU/CRRT Services)
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-General Medical & Surgical Hospitals, Nec8062
Product category
Structural Heart Medical Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales (Future)
TypeHardware Sales
Description

The company is in clinical stage and has not yet generated revenue. The DUO™ System is under clinical investigation and not commercially available in any geography. Upon regulatory approval, the company plans to commercialize its transcatheter tricuspid valve system through direct sales to hospitals and medical centers.

croivalve.com
2Grant Funding
TypeLicensing Royalties
Description

The company receives grant funding from government and EU programs including the European Innovation Council (EIC) and DTIF (Disruptive Technologies Innovation Fund) to support R&D and clinical trials.

croivalve.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1DUO™ System
Description

A novel transcatheter tricuspid coaptation valve system that works in tandem with the native tricuspid valve to restore valve function while preserving native anatomy. Designed for treating severe+ tricuspid regurgitation (TR).

croivalve.com
+1 more record
Core offering1 text field

CroíValve develops the DUO™ System, a transcatheter tricuspid coaptation valve designed for the minimally invasive treatment of severe+ tricuspid regurgitation. The system combines a coaptation valve that works in tandem with the native tricuspid valve leaflets and a novel SVC-anchored stent that leaves the right heart and native valve apparatus untouched, enabling treatment of a broad patient population including those with large annulus sizes, pre-existing CEID leads, large coaptation gaps, and advanced disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 89% of patients experienced >15-point improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ)
+7 more records
Product overview1 text field

CroíValve develops the DUO™ System, a transcatheter tricuspid coaptation valve system designed for the minimally invasive treatment of tricuspid regurgitation. The core DUO™ System consists of a coaptation valve, adjustable catheter system, and novel anchor mechanism that works in tandem with the native tricuspid valve. The company has evolved the technology with the DUO Adapt System, which introduces Adaptive Coaptation—a next-generation approach where the coaptation valve optimizes to fill larger, complex leak profiles by adapting to each patient's individual leak shape. Both systems are currently under clinical investigation through the TANDEM I (first-in-human, Europe) and TANDEM II (early feasibility, US/EU) clinical studies.

Product and service2 records
1DUO™ System
CategoryStructural Heart Medical Devices
Description

The DUO™ System is a transcatheter tricuspid coaptation valve system consisting of a coaptation valve that fills the leak and adapts to varying anatomy, an adjustable catheter delivery system, and a novel SVC stent-based anchor that preserves the right heart and native valve apparatus. It is designed for interventional cardiologists and cardiac surgeons treating patients with severe or greater symptomatic tricuspid regurgitation.

2DUO Adapt System
CategoryStructural Heart Medical Devices
Description

The DUO Adapt System is an enhanced iteration of the DUO System with an optimized coaptation valve that adapts to each patient's individual leak shape, introducing a new treatment category called Adaptive Coaptation. It is designed to fill larger, more complex leak profiles and is under clinical investigation in the expanded TANDEM II Study.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global structural heart leader with the Evoque transcatheter tricuspid valve replacement system (FDA-approved 2024). Competes directly with CroíValve in the tricuspid regurgitation market but operates across a much broader portfolio including TAVR and mitral valve devices.

2Abbott
TypeBroad incumbent
Description

Major medtech incumbent with the TriClip transcatheter tricuspid repair system (FDA-approved 2024). Also offers MitraClip and a comprehensive structural heart portfolio. Competes directly with CroíValve's DUO System in the TR treatment market.

TypeBroad incumbent
Description

Large medtech incumbent with structural heart programs and historical involvement in tricuspid interventions. Serves as both a potential competitor and benchmark; multiple CroíValve executives are Medtronic alumni (CEO O'Keeffe, VP R&D Kenny, board members Ryan).

TypeDirect peer
Description

Emerging structural heart company developing the AltaValve system for mitral and tricuspid regurgitation. Directly comparable as a clinical-stage transcatheter tricuspid device developer pursuing the same market opportunity as CroíValve.

TypeDirect peer
Description

Clinical-stage medical device company developing transcatheter tricuspid valve replacement (Saturn TMVR system applicable to tricuspid). Comparable as a peer-stage competitor in transcatheter tricuspid therapy with board representation from industry veterans (Azin Parhizgar also serves on InnovHeart board).

TypeDirect peer
Description

Developer of the Carillon System for functional tricuspid and mitral regurgitation. Comparable as a transcatheter tricuspid intervention company pursuing the same patient population with a different mechanical approach (annuloplasty-based).

TypeDirect peer
Description

Clinical-stage structural heart company developing the DurAVR THV system for aortic stenosis and tricuspid applications. Comparable as a clinical-stage transcatheter valve developer with similar regulatory pathway and structural heart focus.

TypeEmerging player
Description

Early-stage company developing transcatheter solutions for tricuspid and mitral regurgitation. Comparable as a smaller emerging player in the structural heart space with overlapping target indications though currently less advanced in clinical development.

TypeBroad incumbent
Description

Major medtech incumbent with structural heart programs and historical acquisition activity in tricuspid space (acquired Claret Medical). Multiple CroíValve board members are Boston Scientific veterans (Chairman Collins was VP International Operations). Represents both a competitive threat and potential strategic acquirer.

TypeOthers
Description

Interventional heart failure company developing transcatheter devices for structural heart disease. Comparable as an adjacent structural heart device developer with similar clinical-stage profile and regulatory pathway, though focused on interatrial shunting rather than tricuspid repair.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CroíValve

Structural Heart Medical Devicescroivalve.com

CroíValve is a clinical-stage medical device company developing the DUO™ System, a transcatheter tricuspid coaptation valve that works with the native valve to treat severe Tricuspid Regurgitation, currently in FDA early feasibility studies targeting an estimated 4M+ patients in the US and EU.

What CroíValve does

CroíValve is a clinical-stage medical device company developing the DUO™ System, a transcatheter tricuspid coaptation valve for the minimally invasive treatment of severe or greater symptomatic Tricuspid Regurgitation (TR). The device is designed to fill the regurgitant leak by working in tandem with the native tricuspid valve leaflets, preserving native anatomy and remaining independent of annulus size and coaptation gap. It is anchored in the Superior Vena Cava (SVC) via a stent, leaving the right heart and native valve apparatus untouched, and is compatible with pre-existing cardiac implantable electronic device (CEID) leads. The product line now includes the DUO Adapt System, which introduces "Adaptive Coaptation" capable of treating very large leaks up to 35mm.

The company's go-to-market is structured around clinical evidence generation rather than commercial sales. Two ongoing studies support the technology: TANDEM I (first-in-human, completed in Europe with 10 patients showing 89% KCCQ improvement, 100% NYHA Class I/II at 6 months, zero pacemaker events, and 100% survival) and TANDEM II (FDA-approved Early Feasibility Study underway at US and EU sites including Piedmont Heart Institute, with more than 15 patients treated and expanding). The DUO System is not commercially available in any geography, and the company has stated no pricing. Future commercialization is planned through direct sales to hospitals and heart valve centers following regulatory approval.

CroíValve is headquartered in Dublin, Ireland with R&D and Operations in Galway, and Clinical/Regulatory functions in the United States. Founded in 2016 by Dr. Martin Quinn (an interventional cardiologist who performed Ireland's first TAVI in 2008) and Dr. Lucy O'Keeffe (ex-Medtronic transcatheter aortic program), the company has raised approximately $43 million including grants through a Series A (€8M, 2022), Series B ($16M, 2024), an EIC Accelerator award (€2.5M grant + €10M equity commitment, 2025), and a Series B expansion ($20M + $7M grants, 2026). Key investors include MedTech Syndicate, BGF, the European Innovation Council, Broadview Ventures, HBAN MedTech, Irrus Syndicates, Enterprise Ireland, IAG Capital Partners, Ascentifi, Furthr, Atlantic Bridge University Fund, Elkstone, and SOSV.

CroíValve firmographics

Firmographics
Name
CroíValve
Legal name
CroíValve
Website
https://croivalve.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
CroíValve is a clinical-stage medical device company developing the DUO™ System, a transcatheter tricuspid coaptation valve that works with the native valve to treat severe Tricuspid Regurgitation, currently in FDA early feasibility studies targeting an estimated 4M+ patients in the US and EU.
Ownership category
akta.pro rank

CroíValve industry classification

Industry
Product category
Structural Heart Medical Devices
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-General Medical & Surgical Hospitals, Nec (8062)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKAHAN
Critical Care Nephrology (ICU/CRRT Services)

Keywords

  • Transcatheter heart valve
  • Tricuspid regurgitation device
  • Structural heart intervention
  • Minimally invasive cardiac implant
  • Coaptation valve system

Where CroíValve is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices3 records

Markets served

CroíValve business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device Sales (Future): The company is in clinical stage and has not yet generated revenue. The DUO™ System is under clinical investigation and not commercially available in any geography. Upon regulatory approval, the company plans to commercialize its transcatheter tricuspid valve system through direct sales to hospitals and medical centers.
  2. Grant Funding: The company receives grant funding from government and EU programs including the European Innovation Council (EIC) and DTIF (Disruptive Technologies Innovation Fund) to support R&D and clinical trials.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

CroíValve product offering

Product offering

Core offering

CroíValve develops the DUO™ System, a transcatheter tricuspid coaptation valve designed for the minimally invasive treatment of severe+ tricuspid regurgitation. The system combines a coaptation valve that works in tandem with the native tricuspid valve leaflets and a novel SVC-anchored stent that leaves the right heart and native valve apparatus untouched, enabling treatment of a broad patient population including those with large annulus sizes, pre-existing CEID leads, large coaptation gaps, and advanced disease.

Product overview

CroíValve develops the DUO™ System, a transcatheter tricuspid coaptation valve system designed for the minimally invasive treatment of tricuspid regurgitation. The core DUO™ System consists of a coaptation valve, adjustable catheter system, and novel anchor mechanism that works in tandem with the native tricuspid valve. The company has evolved the technology with the DUO Adapt System, which introduces Adaptive Coaptation—a next-generation approach where the coaptation valve optimizes to fill larger, complex leak profiles by adapting to each patient's individual leak shape. Both systems are currently under clinical investigation through the TANDEM I (first-in-human, Europe) and TANDEM II (early feasibility, US/EU) clinical studies.

Differentiator

Problem solved

Functional benefit

Brands

  • DUO™ System: A novel transcatheter tricuspid coaptation valve system that works in tandem with the native tricuspid valve to restore valve function while preserving native anatomy. Designed for treating severe+ tricuspid regurgitation (TR).
  • DUO Adapt System

Products and services

  • DUO™ System The DUO™ System is a transcatheter tricuspid coaptation valve system consisting of a coaptation valve that fills the leak and adapts to varying anatomy, an adjustable catheter delivery system, and a novel SVC stent-based anchor that preserves the right heart and native valve apparatus. It is designed for interventional cardiologists and cardiac surgeons treating patients with severe or greater symptomatic tricuspid regurgitation.
  • DUO Adapt System The DUO Adapt System is an enhanced iteration of the DUO System with an optimized coaptation valve that adapts to each patient's individual leak shape, introducing a new treatment category called Adaptive Coaptation. It is designed to fill larger, more complex leak profiles and is under clinical investigation in the expanded TANDEM II Study.

Quantifiable outcome

  • 89% of patients experienced >15-point improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ)
  • +7 more outcomes

Companies that use CroíValve

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles1 record

CroíValve technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

CroíValve partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

CroíValve competitors and assessment

Company assessment

Broad incumbents

  • Edwards Lifesciences: Global structural heart leader with the Evoque transcatheter tricuspid valve replacement system (FDA-approved 2024). Competes directly with CroíValve in the tricuspid regurgitation market but operates across a much broader portfolio including TAVR and mitral valve devices.
  • Abbott: Major medtech incumbent with the TriClip transcatheter tricuspid repair system (FDA-approved 2024). Also offers MitraClip and a comprehensive structural heart portfolio. Competes directly with CroíValve's DUO System in the TR treatment market.
  • Medtronic: Large medtech incumbent with structural heart programs and historical involvement in tricuspid interventions. Serves as both a potential competitor and benchmark; multiple CroíValve executives are Medtronic alumni (CEO O'Keeffe, VP R&D Kenny, board members Ryan).
  • Boston Scientific: Major medtech incumbent with structural heart programs and historical acquisition activity in tricuspid space (acquired Claret Medical). Multiple CroíValve board members are Boston Scientific veterans (Chairman Collins was VP International Operations). Represents both a competitive threat and potential strategic acquirer.

Direct peers

  • 4C Medical Technologies: Emerging structural heart company developing the AltaValve system for mitral and tricuspid regurgitation. Directly comparable as a clinical-stage transcatheter tricuspid device developer pursuing the same market opportunity as CroíValve.
  • InnovHeart: Clinical-stage medical device company developing transcatheter tricuspid valve replacement (Saturn TMVR system applicable to tricuspid). Comparable as a peer-stage competitor in transcatheter tricuspid therapy with board representation from industry veterans (Azin Parhizgar also serves on InnovHeart board).
  • Cardiac Dimensions: Developer of the Carillon System for functional tricuspid and mitral regurgitation. Comparable as a transcatheter tricuspid intervention company pursuing the same patient population with a different mechanical approach (annuloplasty-based).
  • Anteris Technologies: Clinical-stage structural heart company developing the DurAVR THV system for aortic stenosis and tricuspid applications. Comparable as a clinical-stage transcatheter valve developer with similar regulatory pathway and structural heart focus.

Emerging players

  • Micro Interventional Devices: Early-stage company developing transcatheter solutions for tricuspid and mitral regurgitation. Comparable as a smaller emerging player in the structural heart space with overlapping target indications though currently less advanced in clinical development.

Others

  • Corvia Medical: Interventional heart failure company developing transcatheter devices for structural heart disease. Comparable as an adjacent structural heart device developer with similar clinical-stage profile and regulatory pathway, though focused on interatrial shunting rather than tricuspid repair.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks1 record

Key highlights6 records

Customer concentration

CroíValve social profiles

Digital presence

CroíValve financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CroíValve leadership team

Management profile

Number of profiles

Profiles11 records

CroíValve funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CroíValve M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CroíValve

What does CroíValve do?

CroíValve develops the DUO™ System, a transcatheter tricuspid coaptation valve designed for the minimally invasive treatment of severe+ tricuspid regurgitation. The system combines a coaptation valve that works in tandem with the native tricuspid valve leaflets and a novel SVC-anchored stent that leaves the right heart and native valve apparatus untouched, enabling treatment of a broad patient population including those with large annulus sizes, pre-existing CEID leads, large coaptation gaps, and advanced disease.

Is CroíValve a public or private company?

CroíValve is a private company. It is classified as venture growth investor backed and is currently operating.

When was CroíValve founded?

CroíValve was founded in 2016. It employs 51 to 100 people.

Where is CroíValve based?

CroíValve is headquartered in Dublin, Ireland, in the Europe region.

How does CroíValve make money?

Two revenue lines are on record. Medical Device Sales (Future) is the primary driver. The others are grant Funding.

Who are CroíValve's main competitors?

Broad incumbents on record are Edwards Lifesciences, Abbott, Medtronic and Boston Scientific. Direct peers are 4C Medical Technologies, InnovHeart, Cardiac Dimensions and Anteris Technologies. Micro Interventional Devices is listed as an emerging player. Corvia Medical is listed as an others.

Does CroíValve have an API?

No public API is recorded for CroíValve.

What industry is CroíValve in?

CroíValve's product category is Structural Heart Medical Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAKAHAN, Critical Care Nephrology (ICU/CRRT Services). Its NAICS code is 54151 and its SIC code is 8062.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MassDeviceCroíValve picks longtime Edwards leader as new CEOCroíValve appointed Jaime Wheeler as its new CEO, with Lucy O'Keeffe transitioning to COO, as the company advances toward commercialization of its Duo Adapt coaptation platform for treating tricuspid regurgitation. Wheeler brings over 25 years of medtech experience, most recently serving as SVP of global clinical affairs for Transcatheter Heart Valves at Edwards, where she spent 12 years advancing transcatheter structural heart technology. The company recently announced new funding to support an expanded TANDEM II study of the Duo Adapt system, which uses a novel anchor system delivered via percutaneous techniques.AijournCroíValve Announces the Appointment of Jaime Wheeler as Chief Executive OfficerCroíValve, a clinical-stage medical device company developing the DUO transcatheter tricuspid coaptation valve system, has appointed Jaime Wheeler as Chief Executive Officer, with Lucy O’Keeffe transitioning to Chief Operating Officer. Wheeler brings over 25 years of experience in structural heart innovation, having served as Senior Vice President of Global Clinical Affairs at Edwards Lifesciences where she contributed to the PARTNER trial series. The company, which has its R&D and operations based in Ireland and clinical and regulatory functions in the US, is expanding its US presence and preparing for commercialization of the DUO System.MorningstarCroíValve Announces the Appointment of Jaime Wheeler as Chief Executive OfficerCroíValve appointed Jaime Wheeler as CEO and Lucy O'Keeffe as COO. Wheeler brings over 25 years of experience, including a role at Edwards Lifesciences. The company will expand its TANDEM II study to evaluate the DUO system for tricuspid regurgitation.Pulse 2.0CroíValve Raises $27 Million Additional Capital To Advance DUO Adapt SystemCroíValve closed $20 million in Series B expansion financing along with $7 million in European Innovation Council and DTIF grant financing, bringing its total Series B to $36 million and total capital to $43 million including grants. The funding will support expansion of the TANDEM II Study evaluating the DUO Adapt System, a transcatheter device for treating tricuspid regurgitation, with new clinical sites in the U.S. and Europe. New investors BGF and the European Innovation Council joined the round with existing investors, and representatives from both new investors will join CroíValve's Board as non-executive directors.Silicon RepublicCroíValve adds $20m to Series B, taking round to $36mTrinity College Dublin medical device spin-out CroíValve has closed a $20 million Series B expansion, bringing its total Series B to $36 million ($43 million including grant financing), with new investor BGF joining alongside the MedTech Syndicate. The funding will support an expanded US and EU clinical study of the company's Duo Tricuspid Coaptation Valve System for treating tricuspid regurgitation without invasive surgery. Tim Rea, co-Head of Early Stage investments at BGF, will join CroíValve's board as part of the deal.Medical BuyerCroíValve closes USD 27M Series B expansion financing roundCroíValve announced the closing of a $20 million Series B expansion financing round, plus $7 million in European Innovation Council (EIC) and DTIF grant financing, bringing total Series B funding to $36 million and total funding to $43 million including grants. New investors BGF and EIC joined the round alongside existing MedTech Syndicate investors, with BGF's Tim Rea joining the board. Proceeds will fund an expanded TANDEM II Study evaluating the DUO™ Adapt System for treating tricuspid regurgitation, expanding beyond 15 patients already treated to include additional US and EU clinical sites.Business Wire BlogCroíValve Announces Expansion of Series B Financing with $27 Million Additional Capital to Fund DUO Adapt in an Enlarged TANDEM II StudyCroíValve, a Dublin-based medical device company developing a transcatheter system for tricuspid regurgitation treatment, closed $20 million in Series B expansion financing plus $7 million in EIC and DTIF grant funding, bringing total Series B to $36 million and total capital including grants to $43 million. The financing round included new investors BGF and the European Innovation Council, with BGF's Tim Rea joining the board, and proceeds will fund expansion of the TANDEM II clinical study for the DUO Adapt System beyond the 15 patients already treated to additional US and EU sites.FinancialContent Business PageCroíValve Announces Expansion of Series B Financing with $27 Million Additional Capital to Fund DUO Adapt in an Enlarged TANDEM II StudyCroíValve announced the closing of a $20 million Series B expansion financing plus $7 million in European Innovation Council and DTIF grant financing, bringing total Series B to $36 million and total funding to $43 million. New investors BGF and EIC joined the round alongside existing investors including MedTech Syndicate, with BGF's Tim Rea joining CroíValve's Board of Directors. The proceeds will fund an expanded TANDEM II Study evaluating the DUO Adapt System for treating tricuspid regurgitation, expanding beyond 15 patients already treated to include additional US and EU clinical sites.MassDeviceCroíValve closes expanded Series B at $36MCroíValve closed a $20 million Series B expansion and $7 million in grant financing, bringing total proceeds to $36 million. The funds will support an expanded TANDEM II study of its Duo Adapt system for tricuspid regurgitation. The company plans to add new U.S. and European sites to the study.BioWorldCroívalve secures $27M for Duo Adapt tricuspid deviceCroívalve secured $20 million in series B financing and $7 million in grant funding for its Duo Adapt transcatheter device treating tricuspid regurgitation. The company will use the funds to expand its clinical study evaluating the device's safety and performance in patients with severe or greater symptomatic tricuspid regurgitation.